A TROP2-targeting aptamer enables selective drug delivery and potent antitumor activity in pancreatic cancer
Science Advances · 13.11.2026 · 12 (46)
DOI: 10.1126/sciadv.aee3585 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 13.11.2026. Verfasst von Yuanding Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biliary-Pancreatic Surgery, Institute of Molecular Medicine (IMM), Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, S…. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Cell Adhesion Molecules, Pancreatic Neoplasms, Aptamers, Nucleotide. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Strategic Priority Research Program of the Chinese Academy of Sciences, National Key Research and Development Program of China, Innovation Research Team of High-Level of Local Universities in Shanghai.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains difficult to treat, highlighting the need for strategies that selectively deliver cytotoxic agents to tumor cells. Trophoblast cell-surface antigen 2 (TROP2) has been proposed as a candidate therapeutic target in PDAC, but non-antibody-based delivery formats remain underexplored. Using protein-SELEX, we identified T17, a high-affinity aptamer that specifically binds to TROP2, and conjugated it to monomethyl auristatin E through an MC-Val-Cit-PAB linker to generate the aptamer-drug conjugate T17-M. Preclinical evaluation in cellular and animal models showed that T17-M retained TROP2-dependent binding, underwent clathrin-mediated internalization and lysosomal processing, and suppressed tumor growth in cell-line-derived and patient-derived xenografts. T17-M also reduced liver metastasis and induced calreticulin exposure, ATP release, and HMGB1 secretion, consistent with immunogenic cell death. In immunocompetent models, T17-M promoted dendritic-cell activation and CD8 + T cell infiltration, while its combination with PD-1 blockade further enhanced tumor control and prolonged survival. These findings provide preclinical proof-of-concept for T17-M as an alternative TROP2-targeted drug-delivery strategy for PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biliary-Pancreatic Surgery, Institute of Molecular Medicine (IMM), Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
- College of Chemistry and Materials Science, Materials and Chemical Engineering, Shanghai Normal University, Shanghai 200234, China.
ORCID-Profile: Yuanding Liu, Zhaofeng Luo, Yuan Gao, Tao Pan, Yingbin Liu, Yang Sun, Weihong Tan
Förderung
- Strategic Priority Research Program of the Chinese Academy of Sciences
- National Key Research and Development Program of China
- Innovation Research Team of High-Level of Local Universities in Shanghai
Zitieren
APA
Liu, Y., Luo, Z., Gao, Y., Pan, T., Yang, C., Zhang, Z., Yu, D., He, Y., Chen, D., Guo, S., Liu, Y., Sun, Y., & Tan, W. (2026). A TROP2-targeting aptamer enables selective drug delivery and potent antitumor activity in pancreatic cancer. Science Advances, 12(46). https://doi.org/10.1126/sciadv.aee3585
Vancouver
Liu Y, Luo Z, Gao Y, Pan T, Yang C, Zhang Z, et al. A TROP2-targeting aptamer enables selective drug delivery and potent antitumor activity in pancreatic cancer. Science Advances. 2026;12(46). doi:10.1126/sciadv.aee3585
BibTeX
@article{Liu2026,
author = {Liu, Yuanding and Luo, Zhaofeng and Gao, Yuan and Pan, Tao and Yang, Changjie and Zhang, Zheng and Yu, Die and He, Yifan and Chen, Daiquan and Guo, Sainan and Liu, Yingbin and Sun, Yang and Tan, Weihong},
title = {A TROP2-targeting aptamer enables selective drug delivery and potent antitumor activity in pancreatic cancer},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {46},
doi = {10.1126/sciadv.aee3585}
}
EUVIMED